Aristides Capital LLC Lowers Holdings in BioNTech SE Sponsored ADR $BNTX

Key Points

• Aristides Capital LLC reduced its stake in BioNTech by 19.3%, owning 14,533 shares worth approximately $1.32 million after selling 3,477 shares in the 1st quarter.
• Significant institutional activity includes Bank of New York Mellon increasing its holdings by 18,892.9% and several others boosting their positions, resulting in 15.52% of the stock owned by institutional investors.
• Analysts set a consensus target price of $135.80 for BioNTech, with various ratings including a "buy" from Bank of America, while the stock recently reported a 5.2% decline in value.

Aristides Capital LLC trimmed its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 19.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 14,533 shares of the company's stock after selling 3,477 shares during the quarter. Aristides Capital LLC's holdings in BioNTech were worth $1,323,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in BNTX. Probity Advisors Inc. raised its position in BioNTech by 8.5% in the fourth quarter. Probity Advisors Inc. now owns 1,970 shares of the company's stock worth $224,000 after acquiring an additional 154 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of BioNTech by 9.1% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,494 shares of the company's stock worth $227,000 after purchasing an additional 209 shares during the period. SBI Securities Co. Ltd. increased its stake in shares of BioNTech by 7.1% in the 1st quarter. SBI Securities Co. Ltd. now owns 3,673 shares of the company's stock worth $334,000 after acquiring an additional 244 shares in the last quarter. Banque Cantonale Vaudoise bought a new position in shares of BioNTech in the 1st quarter worth about $36,000. Finally, GF Fund Management CO. LTD. lifted its position in BioNTech by 22.0% in the 1st quarter. GF Fund Management CO. LTD. now owns 2,514 shares of the company's stock valued at $229,000 after acquiring an additional 453 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BNTX has been the topic of a number of research reports. Leerink Partners set a $112.00 price objective on shares of BioNTech in a report on Monday, June 2nd. The Goldman Sachs Group assumed coverage on shares of BioNTech in a report on Thursday, May 29th. They issued a "neutral" rating and a $110.00 target price on the stock. Truist Financial reissued a "buy" rating and issued a $155.00 target price (up previously from $151.00) on shares of BioNTech in a report on Tuesday, June 3rd. Citigroup restated a "buy" rating and issued a $140.00 price target (down previously from $145.00) on shares of BioNTech in a research report on Tuesday, May 6th. Finally, JPMorgan Chase & Co. cut their price objective on shares of BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a research report on Thursday, May 22nd. Thirteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, BioNTech presently has an average rating of "Moderate Buy" and a consensus target price of $135.80.

BioNTech Price Performance

BioNTech stock traded down $1.93 during trading on Friday, reaching $100.00. The company had a trading volume of 505,409 shares, compared to its average volume of 929,146. The firm has a market capitalization of $24.04 billion, a PE ratio of -62.50 and a beta of 1.23. The firm's 50-day simple moving average is $109.79 and its 200 day simple moving average is $105.18. BioNTech SE Sponsored ADR has a 1-year low of $81.20 and a 1-year high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.48 and a current ratio of 8.61.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($1.41) by ($0.19). BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The business had revenue of $306.46 million during the quarter, compared to analysts' expectations of $161.26 million. During the same period in the prior year, the business posted ($3.36) earnings per share. The business's quarterly revenue was up 102.6% on a year-over-year basis. BioNTech has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.